Ms Pip Marks

Events

Jul 31

Dr Phillip Read – Responding to developments blood borne virus prevention and treatment: Integrating science and...

Jul 10

NAIDOC Special Event: Celebrating Indigenous women in health and justice research

Jul 03

Stefanie Vaccher – “Drugs don’t work in people who don’t take them” – Adherence to HIV pre-exposure prophylaxis (PrEP)

Publications

Journal articles

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4

Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, vol. 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007

Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, vol. 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844

Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0150655

Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, vol. 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003

Giarda P; Avihingsanon A; Sasadeusz J; Audsley J; Marks P; Matthews G; Ruxrungtham K; Lewin SR; Crane M, 2014, 'CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy', Antiviral Therapy, vol. 19, pp. 429 - 433, http://dx.doi.org/10.3851/IMP2720

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC³Study', Journal of Clinical Virology, vol. 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027

Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', Journal of Nursing Administration, vol. 44, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150

Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', European Journal of Gastroenterology and Hepatology, vol. 26, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150

Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, vol. 31, pp. 33 - 33, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000311236700104&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Avihingsanon A; Matthews GV; Lewin SR; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Dore GJ; Ruxrungtham K, 2012, 'Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand', AIDS Research and Therapy, vol. 9, http://dx.doi.org/10.1186/1742-6405-9-6

Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M, 2012, 'Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology (Australia), vol. 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Crawford DHG; Dore GJ; Sievert W; Cheng WSC; Weltman M; McCaughan G; Rawlinson W; Marks PS; Yoshihara M; Rizkalla B, 2012, 'Early on-treatment viral load and baseline METAVIR score: Improved prediction of sustained virological response in HCV genotype 1 patients', Antiviral Therapy, vol. 17, pp. 849 - 854, http://dx.doi.org/10.3851/IMP2104

Matthews GV; Pham ST; Hellard M; Grebely J; Zhang L; Oon A; Marks P; Van Beek I; Rawlinson W; Kaldor JM, 2011, 'Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C', Clinical Infectious Diseases, vol. 52, pp. 803 - 811, http://dx.doi.org/10.1093/cid/ciq200

Dore GJ; Hellard M; Matthews GV; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G, 2010, 'Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection', Gastroenterology, vol. 138, http://dx.doi.org/10.1053/j.gastro.2009.09.019

Grebely J; Petoumenos K; Matthews GV; Haber P; Marks P; Lloyd AR; Kaldor JM; Dore GJ; Hellard M, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC study', Drug and Alcohol Dependence, vol. 107, pp. 244 - 249, http://dx.doi.org/10.1016/j.drugalcdep.2009.09.015

Grebely J; Petoumenos K; Hellard M; Matthews GV; Suppiah V; Applegate T; Yeung B; Marks P; Rawlinson W; Lloyd AR, 2010, 'Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection', Hepatology, vol. 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850

Cheng WSC; Roberts SK; McCaughan G; Sievert W; Weltman M; Crawford D; Rawlinson W; Marks PS; Thommes J; Rizkalla B, 2010, 'Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing', Journal of Hepatology, vol. 53, pp. 616 - 623, http://dx.doi.org/10.1016/j.jhep.2010.04.024

Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, vol. 28, pp. A27 - A27, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews GV; Seaberg E; Dore GJ; Bowden S; Lewin SR; Sasadeusz J; Marks P; Goodman Z; Philp FH; Tang Y, 2009, 'Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals', AIDS, vol. 23, pp. 1707 - 1715, http://dx.doi.org/10.1097/QAD.0b013e32832b43f2

Matthews GV; Hellard M; Haber P; Yeung B; Marks P; Baker D; McCaughan G; Sasadeusz J; White P; Rawlinson W, 2009, 'Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C', Clinical Infectious Diseases, vol. 48, pp. 650 - 658, http://dx.doi.org/10.1086/596770

Lewin SR; Ribiero RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ, 2009, 'Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy', Hepatology, vol. 49, pp. 1113 - 1121, http://dx.doi.org/10.1002/hep.22754

Chang JJ; Sirivichayakul S; Avihingsanon A; Thompson AJV; Revill P; Iser D; Slavin J; Buranapraditkun S; Marks P; Matthews G, 2009, 'Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection', Journal of Virology, vol. 83, pp. 7649 - 7658, http://dx.doi.org/10.1128/JVI.00183-09

Roberts SK; Weltman MD; Crawford DHG; McCaughan GW; Sievert W; Cheng WS; Rawlinson W; Desmond PV; Marks PS; Yoshihara M, 2009, 'Impact of high-dose peginterferon alfa-2a on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial', Hepatology, vol. 50, pp. 1045 - 1055, http://dx.doi.org/10.1002/hep.23130

Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S, 2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand', Hepatology, vol. 48, pp. 1062 - 1069, http://dx.doi.org/10.1002/hep.22462

Conference Papers

Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore GJ, 2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60278-4

Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore G, 2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60062-1

Matthews G; Grebely J; Pham ST; Hellard M; Marks P; Rawlinson W; Kaldor J; Lloyd AR; White PA; Dore GJ, 2009, 'EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, Boston, MA, pp. 668A - 668A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 30 October - 03 November 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000775&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan GW, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, Boston, MA, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 30 October - 03 November 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews GV; Hellard M; Haber PS; Yeung B; Marks P; Rawlinson W; Lloyd A; Kaldor JM; Dore GJ, 2008, 'Frequency of rapid virological response and its utility as a predictor of treatment outcome in individuals treated within the Australian trial in acute hepatitis C (ATAHC)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A337 - A337, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews GV; Hellard M; Haber P; Yeung B; Marks P; Sasadcusz J; Baker D; McCaughan G; White P; Rawlinson W, 2008, 'Frequency of RVR and its utility as a predictor of treatment outcome in individuals treated within the Australian Trial in Acute Hepatitis c (ATAHC)', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Milan, ITALY, pp. S303 - S303, presented at 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Milan, ITALY, 23 - 27 April 2008, http://dx.doi.org/10.1016/S0168-8278(08)60812-0

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks P; Revill PA; Ayres A; Bow-den S; Locarnini S; Thio CL, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in HEPATOLOGY, JOHN WILEY & SONS INC, San Francisco, CA, pp. 712A - 713A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San Francisco, CA, 31 October - 04 November 2008, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401290&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Jones T; Marks P; Connelly C; Fragomeli V; Warner S; Walker P; Ferguson C; Dore GJ, 2008, 'Predictors of HCV treatment uptake and clinical trial participation among patients newly referred for HCV infection: the HCV clinical audit study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A241 - A241, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100133&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews GV; White PA; Hellard M; Grebely J; Marks P; Yeung B; Kaldor JM; Lloyd A; Danta M; Dore GJ, 2008, 'Evidence of sexual transmission of hepatitis C virus infection among HIV-positive men who have sex with men in the Australian trial in acute hepatitis C (ATAHC) study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A365 - A366, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews G; Grebely J; White PA; Renkin MK; Marks P; Ffrench RA; Rawlinson W; Kaldor J; Hellard M; Lloyd AR, 2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in HEPATOLOGY, JOHN WILEY & SONS INC, San Francisco, CA, pp. 1130A - 1131A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San Francisco, CA, 31 October - 04 November 2008, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757402521&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Hellard M; Matthews GV; Petoumenos K; Grebely J; Haber P; Van Beek I; Marks P; Lloyd A; Kaldor J; Dore GJ, 2008, 'Factors associated with uptake of treatment for acute and early chronic hepatitis C virus infection', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A344 - A344, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks PB; Revill P; Ayres A; Bow-den S; Locarnini S; Thio C, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology, 01 January 2008

Crawford D; Robertson SL; Weltman MD; Cheng W; Sievert W; McCaughan G; Desmond PV; Alston A; DePamphilis J; Marks PB, 2008, 'Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: The CHARIOT study', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S290 - S291, presented at Journal of Hepatology, 01 January 2008

Conference Presentations

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; Mchutchison JG; Brainard DM, 2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S274 - S274, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30862-0

Byrne M; Hajarizadeh B; Dore GJ; Treloar C; Marks P; Milat A; Bowman J; McGrath C; Bath N; Calder I, 2017, 'A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S495 - S495, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31387-9

Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G, 2016, 'HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, Vol. 64, pp. S625 - S626, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01163-6

Hajarizadeh B; Grebely J; Byrne M; Marks P; Butler T; Amin J; Vickerman P; Martin NK; McHutchison JG; Brainard DM, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, Boston, MA, Vol. 64, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J, 2015, 'EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, Vol. 62, pp. S657 - S657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 22 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31050-3

Conference Abstracts

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Vertical Tabs